Scholars Central

Conference abstract

Buprenorphine in the treatment of opioid-induced hyperalgesia

Authors: Gregory Rudolf, Jim Walsh, Abigail Plawman, Paul Gianutsos, William Alto, Lloyd Mancl, Vania Rudolf

American Board of Addiction Medicine, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: The clinical effectiveness of a novel non-opioid and benzodiazepine-free protocol was compared to a standardized buprenorphine/naloxone (bup/nx) taper protocol for opioid medically supervised withdrawal and transition to subsequent relapse prevention strategies. Methods: A retrospective chart review of DSM-IV diagnosed opioid-dependent patients admitted for inpatient medically supervised withdrawal examined differences between 84 non-opioid protocol subjects (treated with scheduled 4-day tizanidine, hydroxyzine and gabapentin) and 40 bup/nx protocol subjects (treated with 4-day scheduled bup/nx taper). Both groups received ancillary medications and routine counseling. Primary outcomes were completion of medically supervised withdrawal and facilitation to further chemical dependency treatment. Secondary outcomes included length of hospital stay, Clinical Opiate Withdrawal Scale (COWS) scores, ancillary medication use, adverse effects and initiation of injectable extended release (ER) naltrexone treatment. Results: Non-opioid protocol subjects were more likely to complete medically supervised withdrawal (94% vs. 80%, p=0.026) and engage in further chemical dependency treatment (85% vs. 63%, p=0.006). The non-opioid protocol subjects had a lower incidence of bradycardia (44% vs. 65%, p=0.035) and lower mean COWS scores on day 1 (3.3 vs. 4.8; p<0.001). A total of 27 (32%) subjects in the non-opioid protocol group pursued transition to ER naltrexone and 24 of the 27 (89%) received the injection prior to hospital discharge. Conclusion: This retrospective chart review suggests potential efficacy of a novel protocol, containing no opioids or controlled substances, for medically supervised opioid withdrawal and transition to relapse prevention strategies, including injectable ER naltrexone.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Gregory Rudolf”
  • BylineArticles whose byline prints “Jim Walsh”
  • BylineArticles whose byline prints “Abigail Plawman”
  • BylineArticles whose byline prints “Paul Gianutsos”
  • BylineArticles whose byline prints “William Alto”
  • BylineArticles whose byline prints “Lloyd Mancl”
  • BylineArticles whose byline prints “Vania Rudolf”